This same study also showed that levels of sBTLA remained constant in patients with a variety of cancers who were treated with anti-PD-1, combination therapy (of anti-PD-1 plus anti-CTLA4) or other ICI (Table S1) [83]. This evidence concerns the gene PDCD1 and cancer.